← Back
Data updated: Mar 29, 2026
Johnson & Johnson
JNJ OncologyImmunologyInfectious Disease
Big Pharma
Diversified healthcare company with pharmaceutical, medical devices, and consumer health divisions. Key drugs include Darzalex, Stelara, and Tremfya. Recently spun off consumer health as Kenvue.
$88.1B
Revenue (2024)
$375.0B
Market Cap
-
Trials
134
Approved (2yr)
Key Drugs
Top Drug Revenues Pro
Loading...
Revenue Over Time Pro
Loading...
Competitive Matchups Pro
Loading...
Loading...
Recent Activity
RYBREVANT FASPROI 2026-02-13
Type 5 - New Formulation or New Manufacturer
DARZALEX FASPRO 2026-02-12
Labeling
CONCERTA 2026-02-02
Labeling
CONCERTA 2026-02-02
Labeling
CONCERTA 2026-02-02
Labeling
ESTRADIOL 2026-02-02
DARZALEX FASPRO 2026-01-27
Efficacy
SPRAVATO 2026-01-23
REMS
SEC Filings
Pro
Loading...
Therapeutic Areas
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Oncology 52%
13 drugs Phase 3: 2 Phase 2: 3 Phase 1: 15
Immunology 24%
5 drugs Phase 3: 4 Phase 1: 3
Infectious Disease 11%
3 drugs Phase 2: 1 Phase 1: 2
Cardiovascular 8%
2 drugs Phase 3: 1
Metabolic 6%
2 drugs Phase 1: 1
Pipeline Forecast
Loading...
Loading...
Upcoming Trial Milestones Pro
Loading...
Patent Cliff Pro
Loading...
Loading...
Loading...
Competitors by Therapeutic Area
Merck big-pharma
Oncology, Infectious Disease, Cardiovascular, Immunology, Metabolic
Sanofi big-pharma
Metabolic, Oncology, Infectious Disease, Immunology
AstraZeneca big-pharma
Oncology, Cardiovascular, Metabolic, Immunology
Pfizer big-pharma
Oncology, Infectious Disease, Immunology
COSETTE other
Cardiovascular, Infectious Disease, Immunology, Oncology
Active (46)
RYBREVANT FASPROI RYBREVANT FASPRO INLEXZO IMAAVY LAZCLUZE EDURANT PED AKEEGA TALVEY TECVAYLI RYBREVANT DARZALEX FASPRO BALVERSA SPRAVATO SYMTUZA ERLEADA TREMFYA INVOKAMET XR DARZALEX YONDELIS INVEGA HAFYERA INVEGA TRINZA PREZCOBIX INVOKAMET SIMPONI ARIA INVOKANA SIRTURO XARELTO EDURANT ZYTIGA STELARA INVEGA SUSTENNA SIMPONI INTELENCE PREZISTA ORTHO TRI-CYCLEN 28 ORTHO TRI-CYCLEN 21 RISPERDAL CONSTA CONCERTA REMICADE TOPAMAX ELMIRON NICOTROL ESTRADIOL REOPRO RISPERDAL SPORANOX
Discontinued (93)
HALDOL TOPAMAX SPRINKLE INVEGA ORTHO TRI-CYCLEN ULTRAM ULTRACET RAZADYNE ER ACUVUE THERAVISION WITH KETOTIFEN MICRONOR VERMOX RAZADYNE DITROPAN XL DURAGESIC-100 DURAGESIC-37 DURAGESIC-25 DURAGESIC-75 DURAGESIC-12 DURAGESIC-50 LEVAQUIN TYLENOL W/ CODEINE NO. 4 TYLENOL W/ CODEINE NO. 3 TYLENOL W/ CODEINE NO. 1 TYLENOL W/ CODEINE NO. 2 SUDAFED 12 HOUR OLYSIO ORTHO-NOVUM 1/35-28 ORTHO CYCLEN-28 ORTHO CYCLEN-21 ORTHO EVRA ORTHO-CEPT MODICON 28 ORTHO-NOVUM 7/7/7-28 ORTHO-NOVUM 7/7/7-21 ORTHO TRI-CYCLEN LO AXERT LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER IMODIUM GRIFULVIN V TERAZOL 3 TERAZOL 7 NIZORAL FLEXERIL LEUSTATIN DITROPAN FLOXIN VIADUR ORTHO-NOVUM 10/11-28 ORTHO-NOVUM 10/11-21 TOLECTIN DS TOLECTIN 600
+43 more
Company Info
- First Approval
- 1945-09-12
- Latest
- 2026-02-13
- Applications
- 150
FDA Sponsor Names
JANSSEN PHARMSORTHO MCNEIL PHARMCENTOCOR INCJOHNSON AND JOHNSONMCNEIL CONSUMER +12